Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2021 | Artificial intelligence in myeloma

Jill Corre • 9 Sep 2021
IMW 2021
Multiple Myeloma

Jill Corre, PharmD, PhD, of L’Institut Universitaire du Cancer de Toulouse-Oncopole, Centre Hospitalier Universitaire, Toulouse, France, discusses machine learning, a branch of artificial intelligence, and its prospects in the field of myeloma treatment and diagnosis. Dr Corre explains that adopting machine learning may be a crucial step in the advancement for myeloma, such as for the identification of high-risk patients with complex disease. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.

More from Jill Corre

Updates in the genomics of SMM & multiple myeloma
Francesco Maura et al. • 15 Apr 2023
1:57
Using molecular abnormalities for risk stratification in multiple myeloma at the time of diagnosis
Jill Corre • 12 May 2023
2:20
Novel technologies and the prognostic value of identifying subclones in myeloma
Jill Corre • 12 May 2023
2:02
The impact of heterogeneity on outcomes in multiple myeloma
Jill Corre • 30 Aug 2022

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals